In a report released yesterday, Gregory Renza from RBC Capital maintained a Buy rating on Jasper Therapeutics (JSPR – Research Report), with a price target of $68.00. The company’s shares closed yesterday at $22.69.
According to TipRanks, Renza is a 5-star analyst with an average return of 16.8% and a 48.28% success rate. Renza covers the Healthcare sector, focusing on stocks such as Exelixis, Viridian Therapeutics, and Amgen.
Jasper Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $71.00, which is a 212.91% upside from current levels. In a report released today, JMP Securities also maintained a Buy rating on the stock with a $70.00 price target.
Based on Jasper Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $14.58 million. In comparison, last year the company had a GAAP net loss of $17.54 million
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Jasper Therapeutics (JSPR) Company Description:
Amplitude Healthcare Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
Read More on JSPR:
- Jasper Therapeutics Advances in Antibody Therapy Development
- Jasper Therapeutics reports Q3 EPS ($1.24), consensus ($1.07)
- Jasper Therapeutics commences open-label extension study of chronic urticarias
- Jasper Therapeutics management to meet virtually with Jefferies
- Jasper shows ‘good responses’ for briquilimab in CIndU, says Stifel
